Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY1 | P47900 | 6/20 | 0.95 |
| ▸ | ENPP1 | P22413 | 4/20 | 0.95 |
| ▸ | P2RY11 | Q96G91 | 3/20 | 0.95 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.95 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.95 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.95 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.95 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.93 |
| ▸ | BLM | P54132 | 2/20 | 0.79 |
| ▸ | LMNA | P02545 | 1/20 | 0.79 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.79 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.79 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL375601 | 0.97 | P2RY1 (1.00) | P2RY1ENPP1P2RY11P2RX1P2RX3 | |
| SCHEMBL375602 | 0.97 | P2RY1 (1.00) | P2RY1ENPP1P2RY11P2RX1P2RX3 | |
| SCHEMBL10120953 | 0.97 | P2RY1 (1.00) | P2RY1ENPP1P2RY11P2RX1P2RX3 | |
| SCHEMBL29381860 | 0.97 | P2RY1 (1.00) | P2RY1ENPP1P2RY11P2RX1P2RX3 | |
| SCHEMBL18089797 | 0.97 | P2RY1 (1.00) | P2RY1ENPP1P2RY11P2RX1P2RX3 | |
| SCHEMBL195864 | 0.96 | P2RY1 (1.00) | P2RY1ENPP1P2RY11P2RX1P2RX3 | |
| SCHEMBL195865 | 0.96 | P2RY1 (1.00) | P2RY1ENPP1P2RY11P2RX1P2RX3 | |
| SCHEMBL18089710 | 0.96 | P2RY1 (1.00) | P2RY1ENPP1P2RY11P2RX1P2RX3 | |
| SCHEMBL18089712 | 0.96 | P2RY1 (0.89) | P2RY1ENPP1P2RY11P2RX1P2RX3 | |
| SCHEMBL13099174 | 0.93 | P2RY1 (1.00) | P2RY1ENPP1P2RY11P2RX1P2RX3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2364086-B1 | NOVEL ANTITHROMBOTIC DIADENOSINE TETRAPHOSPHATES AND RELATED ANALOGS | GLSYNTHESIS INC (US) | 2016-09-14 | — | — | EP | disclosed |
| US-8575127-B2 | Antithrombotic diadenosine tetraphosphates and related analogs | GLSYNTHESIS INC. (US) | 2013-11-05 | — | — | US | disclosed |
| US-8575127-B2 | Antithrombotic diadenosine tetraphosphates and related analogs | GLSYNTHESIS INC. (US) | 2013-11-05 | — | — | US | disclosed |
| US-20110257252-A1 | NOVEL ANTITHROMBOTIC DIADENOSINE TETRAPHOSPHATES AND RELATED ANALOGS | GLSYNTHESIS INC. (US) | 2011-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257252-A1 | NOVEL ANTITHROMBOTIC DIADENOSINE TETRAPHOSPHATES AND RELATED ANALOGS | GP6, P2RY6, PFKP | P2RY1 17/4885ENPP1 80/4885P2RY11 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.